Herceptin production patent

Let me answer that. I think it's probably a breast cancer patient. ER2++ and PR2 ++ and Cerb-B2 were negative. If this is the result, it means that the patient's estrogen receptor and progesterone receptor are both positive. From the treatment point of view, there is one more treatment than the patients with negative receptors, that is, they can continue to take tamoxifen orally after chemotherapy, and some patients take tamoxifen at an early stage, even without chemotherapy. Positive is better than negative. Cerb-B2 is an indicator of poor prognosis. 3+ patients have poor prognosis and can be treated with Herceptin. The prognosis of negative patients is better than that of positive patients.